Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 177 articles: HTML format

Single Articles

October 2025
1. SIGHINOLFI MC, Pallotta G, Assumma S, Panio E, et al
   A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease.
   BJU Int. 2025 Oct 10. doi: 10.1111/bju.70019.
   PubMed     Abstract available
   
   
   
2. MARQUIS A, Schwartz MJ, Armache A, Solosky K, et al
   Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.
   BJU Int. 2025 Oct 9. doi: 10.1111/bju.70014.
   PubMed     Abstract available
   
   
   
3. GILL S, Chen R, Lamb BW, Moore CM, et al
   Interventions for patients with prostate cancer on active surveillance: a narrative review.
   BJU Int. 2025 Oct 6. doi: 10.1111/bju.70005.
   PubMed     Abstract available
   
   
   
4. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
   Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'.
   BJU Int. 2025 Oct 3. doi: 10.1111/bju.70024.
   PubMed    
   
   
   
5. HALL R, Ball R, Bancroft E, Eeles R, et al
   Systematic review of PSA reference intervals in the gender diverse population with prostates.
   BJU Int. 2025;136:568-577.
   PubMed     Abstract available
   
   
   
6. VISSCHER J, Bonevski B, O'Callaghan M
   The association of smoking with urinary and sexual function recovery following radical prostatectomy.
   BJU Int. 2025;136:647-656.
   PubMed     Abstract available
   
   
   
7. LEWICKI P, Ginsburg K, Mmonu N, Labardee C, et al
   What is lost in an average? Identifying distinct post-radical prostatectomy functional recovery profiles.
   BJU Int. 2025;136:633-639.
   PubMed     Abstract available
   
   
   September 2025
8. BONADDIO J, Carll J, Eapen R, Sathianathen N, et al
   The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.
   BJU Int. 2025 Sep 30. doi: 10.1111/bju.70015.
   PubMed     Abstract available
   
   
   
9. VAN DEN EYNDE L, Ost P, Verla W, Everaerts W, et al
   Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer.
   BJU Int. 2025 Sep 20. doi: 10.1111/bju.70006.
   PubMed     Abstract available
   
   
   
10. ZAURITO P, Westerberg M, Garmo H, Gedeborg R, et al
    Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score.
    BJU Int. 2025 Sep 12. doi: 10.1111/bju.16927.
    PubMed     Abstract available
    
    
    
11. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
    PubMed    
    
    
    
12. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Reply to 'Comment on Bertini et al.: area deprivation and PSA screening disparities' and 'Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
    PubMed    
    
    
    
13. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    PubMed     Abstract available
    
    
    
14. VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al
    Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
    BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
    PubMed     Abstract available
    
    
    
15. COLLINS KK, Virdee PS, Roberts N, Oke JL, et al
    Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.
    BJU Int. 2025;136:372-384.
    PubMed     Abstract available
    
    
    
16. BERRENS AC, Buckle T, van Oosterom MN, Slof LJ, et al
    Renal clearance of fluorescent agents can compromise image-guided surgery along the urinary tract.
    BJU Int. 2025;136:515-522.
    PubMed     Abstract available
    
    
    
17. LENI R, Tin AL, Liso N, Carlsson SV, et al
    Magnetic resonance imaging for long-term active surveillance biopsy decision-making.
    BJU Int. 2025;136:500-506.
    PubMed     Abstract available
    
    
    
18. LEPOR H, Persily J, Parry S, Rapoport E, et al
    Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
    BJU Int. 2025;136:447-451.
    PubMed     Abstract available
    
    
    
19. KHAN N, Prezzi D, Raison N, Shepherd A, et al
    Impact of three-dimensional prostate models during robot-assisted radical prostatectomy on surgical margins and functional outcomes.
    BJU Int. 2025;136:420-428.
    PubMed     Abstract available
    
    
    August 2025
20. SATAPATHY P, Mehta R, Sah R
    Comment on 'Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management'.
    BJU Int. 2025 Aug 28. doi: 10.1111/bju.16914.
    PubMed    
    
    
    
21. ZHOU SR, Zhang L, Choi MH, Vesal S, et al
    ProMUS-NET: Artificial intelligence detects more prostate cancer than urologists on micro-ultrasonography.
    BJU Int. 2025 Aug 27. doi: 10.1111/bju.16892.
    PubMed     Abstract available
    
    
    
22. ITO K, Mori K, Kumar R, Sabnis RB, et al
    Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia.
    BJU Int. 2025 Aug 24. doi: 10.1111/bju.16900.
    PubMed     Abstract available
    
    
    
23. CHIAM K, Bang A, Nair-Shalliker V, Caruana M, et al
    Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16896.
    PubMed     Abstract available
    
    
    
24. CHONG B, Chen K
    Reply to 'A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer' by Su et al.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16898.
    PubMed    
    
    
    
25. SU PJ, Shao IH, Lin YH
    A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16897.
    PubMed    
    
    
    
26. FLETCHER SA, Macura KJ, Pavlovich CP
    Author response to comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 17. doi: 10.1111/bju.16869.
    PubMed    
    
    
    
27. OLIVIER J, Vertosick E, Delobel L, Bommelaere T, et al
    Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16884.
    PubMed     Abstract available
    
    
    
28. SANAPALA K, Mehta R, Sah R
    Comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 2. doi: 10.1111/bju.16868.
    PubMed    
    
    
    
29. SANTUCCI J, Stapleton P, Perera M, Ischia J, et al
    Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies.
    BJU Int. 2025 Aug 1. doi: 10.1111/bju.16870.
    PubMed     Abstract available
    
    
    July 2025
30. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency.
    BJU Int. 2025 Jul 30. doi: 10.1111/bju.16875.
    PubMed     Abstract available
    
    
    
31. CARLL J, Shi W, Perera M, Lawrentschuk N, et al
    Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16872.
    PubMed     Abstract available
    
    
    
32. GOTO Y, Urabe F, Ogihara Y, Nakata M, et al
    Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management.
    BJU Int. 2025 Jul 19. doi: 10.1111/bju.16860.
    PubMed     Abstract available
    
    
    
33. ZHANG K, Teoh J, Laguna P, de la Rosette J, et al
    Response to Veldi et al.: 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy' - a critical appraisal.
    BJU Int. 2025 Jul 15. doi: 10.1111/bju.16840.
    PubMed    
    
    
    
34. 
    Prostate cancer: detection, treatment and follow-up.
    BJU Int. 2025;136:2-3.
    PubMed    
    
    
    
35. EID N, Lepor H
    Incidence, surveillance and natural history of high-grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy.
    BJU Int. 2025;136:159-164.
    PubMed     Abstract available
    
    
    
36. HAGMAN A, Lantz A, Grannas D, Carlsson S, et al
    Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups.
    BJU Int. 2025;136:135-142.
    PubMed     Abstract available
    
    
    
37. ROBERTS MJ, Arora S, Yao HH, Hogan D, et al
    Transperineal prostate biopsy under local vs general anaesthesia: a cost-effectiveness analysis.
    BJU Int. 2025;136:128-134.
    PubMed     Abstract available
    
    
    
38. KHATTAK A, Ruta D, Patkar V, Popert R, et al
    Artificial intelligence-driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary NHS centre in the UK.
    BJU Int. 2025 Jul 1. doi: 10.1111/bju.16845.
    PubMed     Abstract available
    
    
    June 2025
39. SCHIEDA N, Morash C, Lavallee LT, Flood TA, et al
    Prostate cancer detection by MRI-ultrasonography fusion transperineal vs transrectal biopsy: a randomised control trial.
    BJU Int. 2025 Jun 27. doi: 10.1111/bju.16831.
    PubMed     Abstract available
    
    
    
40. VELDI VDK, Mehta R, Sah R
    Comment on 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy'.
    BJU Int. 2025 Jun 26. doi: 10.1111/bju.16841.
    PubMed    
    
    
    
41. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
    What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
    BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
    PubMed     Abstract available
    
    
    
42. TOH EA, White J, Clarke J, Hider P, et al
    Variation in prostate cancer assessment and management between Maori and non-Maori in New Zealand.
    BJU Int. 2025 Jun 13. doi: 10.1111/bju.16805.
    PubMed     Abstract available
    
    
    
43. FLETCHER SA, Alshak MN, Lee S, Singla N, et al
    Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions.
    BJU Int. 2025 Jun 12. doi: 10.1111/bju.16816.
    PubMed     Abstract available
    
    
    May 2025
44. LIU J, Woon DTS, Perera M, Lawrentschuk N, et al
    Active surveillance in prostate cancer: when to exit and what are the options?
    BJU Int. 2025 May 19. doi: 10.1111/bju.16744.
    PubMed    
    
    
    
45. ALSHAK MN, Higgins MI, Grutman AJ, Campbell J, et al
    Prostate cancer active surveillance in solid organ transplant: a matched study and literature review.
    BJU Int. 2025 May 14. doi: 10.1111/bju.16777.
    PubMed     Abstract available
    
    
    
46. 
    Recent key papers in prostate cancer.
    BJU Int. 2025;135:710-711.
    PubMed    
    
    
    
47. CHEN DC, Huang S, Papa N, Siva S, et al
    Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
    BJU Int. 2025;135:720-732.
    PubMed     Abstract available
    
    
    
48. GROSSMANN NC, Aschwanden FJ, Cornelius J, Malkmus C, et al
    Impact of patient positioning during surgery on neuropathies after robot-assisted laparoscopic radical prostatectomy: a randomised controlled trial.
    BJU Int. 2025;135:802-809.
    PubMed     Abstract available
    
    
    April 2025
49. SILAGY AW, Woon DTS, Kostos L, Bernardino R, et al
    Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
    BJU Int. 2025 Apr 25. doi: 10.1111/bju.16751.
    PubMed     Abstract available
    
    
    
50. PYRGIDIS N, Chaloupka M, Ebner B, Volz Y, et al
    Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study.
    BJU Int. 2025 Apr 19. doi: 10.1111/bju.16746.
    PubMed     Abstract available
    
    
    
51. HO P, Kaufmann B, Gorin MA
    Case of the Month from the Icahn School of Medicine at Mount Sinai, New York, NY: MRI/TRUS fusion-guided biopsy of a local prostate cancer recurrence using the bladder for image registration.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16698.
    PubMed    
    
    
    
52. SUSHENTSEV N, Comune R, Sinci KA, Blyuss O, et al
    A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16743.
    PubMed    
    
    
    
53. DE VOS II, Marenghi C, Badenchini F, Boeve ER, et al
    Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
    BJU Int. 2025 Apr 14. doi: 10.1111/bju.16727.
    PubMed     Abstract available
    
    
    
54. OLSSON K, Delilovic S, Enelius MB, Hagglund A, et al
    Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study.
    BJU Int. 2025 Apr 6. doi: 10.1111/bju.16735.
    PubMed     Abstract available
    
    
    
55. ZHANG K, Teoh J, Laguna P, Dominguez-Escrig J, et al
    The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy.
    BJU Int. 2025 Apr 4. doi: 10.1111/bju.16720.
    PubMed     Abstract available
    
    
    
56. 
    Correction to "Prostate cancer in transgender women: what does a urologist need to know?".
    BJU Int. 2025 Apr 3. doi: 10.1111/bju.16723.
    PubMed    
    
    
    
57. NOLSOE AB, Logager V, Boesen L, Ostergren PB, et al
    Association of bi-parametric MRI measures with continence after robot-assisted radical prostatectomy.
    BJU Int. 2025;135:603-610.
    PubMed     Abstract available
    
    
    
58. ENGESSER C, Brantner P, Gahl B, Walter M, et al
    3D-printed model for resection of positive surgical margins in robot-assisted prostatectomy.
    BJU Int. 2025;135:657-667.
    PubMed     Abstract available
    
    
    March 2025
59. KAM J, Chalasani V, Goolam AS, Bergersen P, et al
    Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.
    BJU Int. 2025 Mar 6. doi: 10.1111/bju.16654.
    PubMed     Abstract available
    
    
    
60. MAYOR N, Light A, Silvanto A, Cullen E, et al
    Fluorescence confocal microscopy for margin assessment in prostatectomy: IP8-FLUORESCE study protocol.
    BJU Int. 2025;135:502-509.
    PubMed     Abstract available
    
    
    
61. BOESEN L, Norgaard N, Bisbjerg R, Logager V, et al
    Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy.
    BJU Int. 2025;135:465-472.
    PubMed     Abstract available
    
    
    February 2025
62. ORTNER G, Falkenbach F, Kachanov M, Inderhees T, et al
    External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer.
    BJU Int. 2025 Feb 20. doi: 10.1111/bju.16687.
    PubMed     Abstract available
    
    
    
63. XIE S, Liu J, Shen B, Xu H, et al
    Salvage low-dose vs high-dose brachytherapy for radio-recurrent prostate cancer.
    BJU Int. 2025 Feb 9. doi: 10.1111/bju.16639.
    PubMed     Abstract available
    
    
    
64. RODRIGUEZ-SANCHEZ L, Cathelineau X, de Reijke TM, Stricker P, et al
    Refining partial gland ablation for localised prostate cancer: the FALCON project.
    BJU Int. 2025 Feb 4. doi: 10.1111/bju.16669.
    PubMed     Abstract available
    
    
    
65. 
    Outcomes of prostate cancer treatments.
    BJU Int. 2025;135:184-185.
    PubMed    
    
    
    
66. SOPUTRO NA, Ramos-Carpinteyro R, Chavali JS, Pedraza AM, et al
    Predictors for selection of outpatient single-port robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2025;135:249-259.
    PubMed     Abstract available
    
    
    January 2025
67. GNANAPRAGASAM VJ, Keates A, Lophatananon A, Thankapannair V, et al
    The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.
    BJU Int. 2025 Jan 29. doi: 10.1111/bju.16666.
    PubMed     Abstract available
    
    
    
68. PYLVALAINEN J, Talala K, Raitanen J, Rannikko A, et al
    Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result.
    BJU Int. 2025 Jan 22. doi: 10.1111/bju.16641.
    PubMed     Abstract available
    
    
    
69. CHONG B, Saad M, Chong TW, Thng J, et al
    Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
    BJU Int. 2025 Jan 2. doi: 10.1111/bju.16632.
    PubMed     Abstract available
    
    
    
70. CHIU PK, Liu AQ, Lau SY, Teoh JY, et al
    A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
    BJU Int. 2025;135:71-77.
    PubMed     Abstract available
    
    
    December 2024
71. OKHAWERE KE, Razdan S, Beksac AT, Saini I, et al
    Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet((R))) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16617.
    PubMed     Abstract available
    
    
    
72. GELIKMAN DG, Azar WS, Yilmaz EC, Lin Y, et al
    A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16616.
    PubMed     Abstract available
    
    
    
73. NOURMOHAMMADI ABADCHI S, Salles DC, Flannery C, Sama V, et al
    Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
    BJU Int. 2024;134:939-944.
    PubMed     Abstract available
    
    
    
74. MERSEBURGER AS, Agarwal N, Bjartell A, Uemura H, et al
    Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
    BJU Int. 2024;134:982-991.
    PubMed     Abstract available
    
    
    
75. CRISAFI D, Wong BNX, Bolton D, Ischia J, et al
    Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
    BJU Int. 2024;134 Suppl 2:12-13.
    PubMed    
    
    
    
76. ROBERTS MJ, Papa N, Veerman H, de Bie K, et al
    Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
    BJU Int. 2024;134 Suppl 2.
    PubMed     Abstract available
    
    
    November 2024
77. MARTIN A, Mahmoud AM, Britton CJ, Fadel A, et al
    In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
    BJU Int. 2024 Nov 30. doi: 10.1111/bju.16598.
    PubMed     Abstract available
    
    
    
78. SII S, Papa N, Yiu TW, Tempo J, et al
    Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.
    BJU Int. 2024 Nov 28. doi: 10.1111/bju.16597.
    PubMed     Abstract available
    
    
    
79. THIMANSSON E, Axen E, Jaderling F, Styrke J, et al
    A novel approach to integrated prostate cancer diagnostics: insights from MRI, prostate biopsy, and pathology reports in a pilot study.
    BJU Int. 2024 Nov 12. doi: 10.1111/bju.16582.
    PubMed    
    
    
    
80. RAVAL AD, Chen S, Littleton N, Constantinovici N, et al
    Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
    BJU Int. 2024 Nov 12. doi: 10.1111/bju.16577.
    PubMed     Abstract available
    
    
    
81. RANS K, Goffin K, Joniau S, Daugaard G, et al
    The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
    BJU Int. 2024 Nov 6. doi: 10.1111/bju.16574.
    PubMed     Abstract available
    
    
    
82. TAKAHASHI T
    The first step in shared decision-making for prostate cancer screening.
    BJU Int. 2024 Nov 6. doi: 10.1111/bju.16580.
    PubMed    
    
    
    
83. LIU J, Cundy TP, Woon DTS, Desai N, et al
    A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer.
    BJU Int. 2024;134:714-722.
    PubMed     Abstract available
    
    
    
84. MUSI G, Mistretta FA, Ivanova M, de Cobelli O, et al
    Evaluation of margins during radical prostatectomy: confocal microscopy vs frozen section analysis.
    BJU Int. 2024;134:773-780.
    PubMed     Abstract available
    
    
    October 2024
85. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
    BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
    PubMed     Abstract available
    
    
    
86. LI T, Graham PL, Cao B, Nalavenkata S, et al
    Accuracy of MRI in detecting seminal vesicle invasion in prostate cancer: a systematic review and meta-analysis.
    BJU Int. 2024 Oct 22. doi: 10.1111/bju.16547.
    PubMed     Abstract available
    
    
    
87. ANG ZY, Kong YL, Md Nesran ZN, Lee SWH, et al
    Efficacy of decision aid delivery modes in prostate cancer screening: umbrella review and network meta-analysis.
    BJU Int. 2024 Oct 14. doi: 10.1111/bju.16545.
    PubMed     Abstract available
    
    
    
88. LAZAROVICH A, Kristof TW, Steadman S, Dahmen AS, et al
    Prostate cancer and solid organ transplantation: patient management and outcomes.
    BJU Int. 2024 Oct 9. doi: 10.1111/bju.16558.
    PubMed     Abstract available
    
    
    
89. GONZALEZ-SAN SEGUNDO C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, et al
    A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
    BJU Int. 2024;134:568-577.
    PubMed     Abstract available
    
    
    
90. KINNEAR N, Fonseca PC, Ogbechie C, Adam S, et al
    Impact of frozen section on long-term outcomes in robot-assisted laparoscopic prostatectomy.
    BJU Int. 2024;134:608-614.
    PubMed     Abstract available
    
    
    
91. TAYA M, Behr SC, Westphalen AC
    Perspectives on technology: Prostate Imaging-Reporting and Data System (PI-RADS) interobserver variability.
    BJU Int. 2024;134:510-518.
    PubMed     Abstract available
    
    
    
92. SAHNI DS, Morrison J, Leung HY
    Grid-based cognitive diagnostic prostatic biopsy without transrectal ultrasonography.
    BJU Int. 2024;134:659-663.
    PubMed    
    
    
    September 2024
93. FANG AM, Gregg JR, Pettaway C, Ma J, et al
    Whole-body MRI for staging prostate cancer: a narrative review.
    BJU Int. 2024 Sep 22. doi: 10.1111/bju.16514.
    PubMed     Abstract available
    
    
    
94. 
    Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs.
    BJU Int. 2024;134:321-322.
    PubMed    
    
    
    
95. REIJNDERS-BOERBOOM GTJA, Jacobs LMC, Helder LS, Panhuizen IF, et al
    Recovery and immune function after low pressure pneumoperitoneum during robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:416-425.
    PubMed     Abstract available
    
    
    
96. TOUZANI A, D'Agate D, Kesch C, Calleris G, et al
    One-year outcomes of same-day-discharge robot-assisted radical prostatectomy.
    BJU Int. 2024;134:380-382.
    PubMed    
    
    
    
97. OUCHI M, Kitta T, Chiba H, Higuchi M, et al
    Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial.
    BJU Int. 2024;134:398-406.
    PubMed     Abstract available
    
    
    
98. BATES AS, Sharma AD, Camilleri P, Browning L, et al
    'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.
    BJU Int. 2024;134:377-379.
    PubMed    
    
    
    August 2024
99. TAKAHASHI T
    Observational study on screen-detected prostate cancer: case series of empirical clinical practice.
    BJU Int. 2024 Aug 29. doi: 10.1111/bju.16525.
    PubMed    
    
    
    
100. ONG WL, Krishnaprasad K, Bensley J, Steeper M, et al
     Population-based prostate cancer outcomes registries - what have we learned and where are we heading?
     BJU Int. 2024 Aug 19. doi: 10.1111/bju.16487.
     PubMed    
     
     
     
101. GEBOERS B, Scheltema MJ, Jung J, Bakker J, et al
     Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
     BJU Int. 2024 Aug 5. doi: 10.1111/bju.16496.
     PubMed     Abstract available
     
     
     
102. JACEWICZ M, Rud E, Lauritzen P, Baco E, et al
     Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia.
     BJU Int. 2024;134:300-306.
     PubMed     Abstract available
     
     
     
103. FANKHAUSER CD, Malkmus C, Aschwanden F, Baumeister P, et al
     'Igloo' technique for robot-assisted radical prostatectomy - maximum nerve sparing for early recovery of continence and sexual function.
     BJU Int. 2024;134:307-311.
     PubMed    
     
     
     
104. ABUELNAGA M, Gendy R, Yao M, Phelan C, et al
     Impact of definitions on continence outcomes in a series of 1000 robot-assisted radical prostatectomies, time for an internationally agreed definition?
     BJU Int. 2024;134:197-200.
     PubMed    
     
     
     
105. NG KL, Giona S, Barber N
     Feasibility of Aquablation prostate surgery performed as day cases.
     BJU Int. 2024;134:185-186.
     PubMed    
     
     
     July 2024
106. BANCROFT EK
     Response to BJU-2024-0780: RE: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
     BJU Int. 2024 Jul 26. doi: 10.1111/bju.16490.
     PubMed    
     
     
     
107. DAUNGSUPAWONG H, Wiwanitkit V
     RE: 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers'.
     BJU Int. 2024 Jul 26. doi: 10.1111/bju.16489.
     PubMed    
     
     
     
108. YANG J, Xiong X, Wei Q, Yang L, et al
     Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer.
     BJU Int. 2024 Jul 17. doi: 10.1111/bju.16467.
     PubMed    
     
     
     
109. MAURER J, Ambrosini F, Chen Y, Schroeder S, et al
     Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply.
     BJU Int. 2024 Jul 16. doi: 10.1111/bju.16468.
     PubMed    
     
     
     
110. SCHMIDT B, Soerensen SJC, Bhambhvani HP, Fan RE, et al
     External validation of an artificial intelligence model for Gleason grading of prostate cancer on prostatectomy specimens.
     BJU Int. 2024 Jul 11. doi: 10.1111/bju.16464.
     PubMed     Abstract available
     
     
     
111. WENZEL M, Hoeh B, Koll F, Humke C, et al
     Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
     BJU Int. 2024 Jul 10. doi: 10.1111/bju.16462.
     PubMed     Abstract available
     
     
     
112. ARVIDSSON I, Svanemur E, Marginean F, Simoulis A, et al
     Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
     BJU Int. 2024 Jul 4. doi: 10.1111/bju.16456.
     PubMed     Abstract available
     
     
     
113. 
     Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
     BJU Int. 2024;134:4-5.
     PubMed    
     
     
     
114. JUSSILA I, Ahtiainen JP, Laakkonen EK, Siltari A, et al
     Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol.
     BJU Int. 2024;134:110-118.
     PubMed     Abstract available
     
     
     
115. SOPUTRO NA, Chavali JS, Ferguson EL, Ramos-Carpinteyro R, et al
     Complications of single-port robot-assisted radical prostatectomy: multi-institutional analysis from the Single-Port Advanced Research Consortium (SPARC).
     BJU Int. 2024;134:54-62.
     PubMed     Abstract available
     
     
     
116. MORETTI TBC, Magna LA, Reis LO
     Continence criteria of 193 618 patients after open, laparoscopic, and robot-assisted radical prostatectomy.
     BJU Int. 2024;134:13-21.
     PubMed     Abstract available
     
     
     June 2024
117. KATO T, Matsumoto R, Yokomizo A, Tohi Y, et al
     Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
     BJU Int. 2024 Jun 17. doi: 10.1111/bju.16436.
     PubMed     Abstract available
     
     
     
118. BANCROFT EK, Page EC, Brook MN, Pope J, et al
     The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
     BJU Int. 2024 Jun 5. doi: 10.1111/bju.16432.
     PubMed     Abstract available
     
     
     
119. HAHN AW, Manyam GC, Chapin BF, Zhang M, et al
     A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
     BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414.
     PubMed     Abstract available
     
     
     
120. 
     Prostate cancer: To screen, or not to screen? That is the question.
     BJU Int. 2024;133:635-637.
     PubMed    
     
     
     
121. FRANCO A, Ditonno F, Manfredi C, Licari LC, et al
     Robot-assisted single-port transvesical enucleation of the prostate: step-by-step technique and early single-centre experience.
     BJU Int. 2024;133:778-782.
     PubMed    
     
     
     
122. NOLSOE AB, Ostergren PB, Jakobsen H, Jensen CFS, et al
     Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial.
     BJU Int. 2024;133:742-751.
     PubMed     Abstract available
     
     
     
123. MAURER J, Friedemann T, Chen Y, Ambrosini F, et al
     A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy.
     BJU Int. 2024;133:725-732.
     PubMed     Abstract available
     
     
     
124. LENFANT L, Beitone C, Troccaz J, Roupret M, et al
     Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation.
     BJU Int. 2024;133:709-716.
     PubMed     Abstract available
     
     
     
125. ALMEIDA-MAGANA R, Au M, Al-Hammouri T, Dinneen K, et al
     Improving fluorescence confocal microscopy for margin assessment during robot-assisted radical prostatectomy: The LaserSAFE technique.
     BJU Int. 2024;133:677-679.
     PubMed    
     
     
     
126. MAC CURTAIN BM, Sugrue DD, Qian W, O'Callaghan M, et al
     Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis.
     BJU Int. 2024;133:646-655.
     PubMed     Abstract available
     
     
     May 2024
127. GALIETTA E, Strolin S, Lodi-Rizzini E, Castellucci P, et al
     Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
     BJU Int. 2024 May 22. doi: 10.1111/bju.16399.
     PubMed    
     
     
     
128. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
     Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
     BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
     PubMed     Abstract available
     
     
     
129. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
     A review of vitamin use for the prevention or treatment of prostate cancer.
     BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
     PubMed    
     
     
     
130. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
     Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
     BJU Int. 2024 May 9. doi: 10.1111/bju.16394.
     PubMed     Abstract available
     
     
     
131. GRAJALES V, Martini A, Shore ND
     Complications of immuno-oncology care: what urologist should know.
     BJU Int. 2024;133:524-531.
     PubMed     Abstract available
     
     
     
132. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
     Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
     BJU Int. 2024;133:548-554.
     PubMed     Abstract available
     
     
     April 2024
133. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
     Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
     BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
     PubMed     Abstract available
     
     
     
134. STATTIN P, Fleming S, Lin X, Lefresne F, et al
     Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
     PubMed     Abstract available
     
     
     
135. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
     The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
     BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
     PubMed    
     
     
     
136. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
     Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
     BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
     PubMed     Abstract available
     
     
     
137. VICKERS A
     Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
     BJU Int. 2024;133:354-355.
     PubMed    
     
     
     
138. MCNICHOLAS DP, Parr NJ
     Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
     BJU Int. 2024;133:487-490.
     PubMed     Abstract available
     
     
     
139. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
     Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
     BJU Int. 2024;133:432-441.
     PubMed     Abstract available
     
     
     
140. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
     Prostate tumour visualisation with PET: is image fusion with MRI the answer?
     BJU Int. 2024;133 Suppl 4:4-6.
     PubMed    
     
     
     March 2024
141. ALBERTSEN PC
     Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
     BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
     PubMed    
     
     
     
142. TAKAHASHI T
     Endpoint and control group in prostate cancer screening research: public health basics.
     BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
     PubMed    
     
     
     
143. PAK JS, Huang R, Huang WC, Lepor H, et al
     Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
     BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
     PubMed     Abstract available
     
     
     
144. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
     Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
     BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
     PubMed    
     
     
     
145. HAMDY FC, Albertsen PC, Donovan JL
     Screening and active surveillance in prostate cancer: the dilemma continues.
     BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
     PubMed    
     
     
     
146. HUBER J, Karschuck P, Valdix J, Thomas C, et al
     Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
     BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
     PubMed     Abstract available
     
     
     
147. TAKAHASHI T
     Active surveillance in all cases of screen-detected prostate cancer.
     BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
     PubMed    
     
     
     
148. ROKAN N, Reddy D, Dudderidge T
     Focal therapy for prostate cancer - when to refer?
     BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
     PubMed    
     
     
     
149. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
     Evolution of European prostate cancer screening protocols and summary of ongoing trials.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
     PubMed     Abstract available
     
     
     
150. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
     Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
     PubMed     Abstract available
     
     
     
151. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
     Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
     BJU Int. 2024;133:324-331.
     PubMed     Abstract available
     
     
     February 2024
152. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
     Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
     BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
     PubMed    
     
     
     
153. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
     During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
     BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
     PubMed     Abstract available
     
     
     
154. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
     (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
     BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
     PubMed     Abstract available
     
     
     
155. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
     Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
     BJU Int. 2024;133:197-205.
     PubMed     Abstract available
     
     
     
156. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
     International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
     BJU Int. 2024;133:179-187.
     PubMed     Abstract available
     
     
     
157. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
     How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
     BJU Int. 2024;133 Suppl 3:13-14.
     PubMed    
     
     
     
158. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
     The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
     BJU Int. 2024;133 Suppl 3:39-47.
     PubMed     Abstract available
     
     
     January 2024
159. SANCHEZ-SALAS R
     Candid choices: optimising patient selection in prostate cancer focal therapy.
     BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
     PubMed    
     
     
     
160. BESIROGLU H
     Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
     BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
     PubMed    
     
     
     
161. TALWAR R, Akinsola O, Penson DF
     What is cancer? A focus on Grade Group 1 prostate cancer.
     BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
     PubMed     Abstract available
     
     
     
162. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
     Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
     BJU Int. 2024;133:104-111.
     PubMed     Abstract available
     
     
     
163. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
     Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
     BJU Int. 2024;133:112-117.
     PubMed     Abstract available
     
     
     December 2023
164. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
     LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
     PubMed    
     
     
     
165. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
     Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
     PubMed     Abstract available
     
     
     November 2023
166. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
     AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
     BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
     PubMed    
     
     
     
167. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
     Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
     BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
     PubMed     Abstract available
     
     
     
168. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
     Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
     BJU Int. 2023;132:568-574.
     PubMed     Abstract available
     
     
     October 2023
169. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
     CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
     BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
     PubMed     Abstract available
     
     
     
170. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
     Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
     BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
     PubMed     Abstract available
     
     
     
171. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
     PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
     BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
     PubMed     Abstract available
     
     
     
172. TISSOT S, Wynn J, Tran V, Farag M, et al
     Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
     BJU Int. 2023;132:411-419.
     PubMed     Abstract available
     
     
     
173. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
     Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
     BJU Int. 2023;132:397-403.
     PubMed     Abstract available
     
     
     September 2023
174. LEHNER F, Crippa A, Sigg S, Eberli D, et al
     Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
     BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
     PubMed     Abstract available
     
     
     
175. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
     Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
     BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
     PubMed     Abstract available
     
     
     
176. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
     Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
     BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
     PubMed     Abstract available
     
     
     June 2023
177. BRANT A, Campi R, Carrion DM, Esperto F, et al
     Findings from an international survey of urology trainee experience with prostate biopsy.
     BJU Int. 2023;131:705-711.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.